David Pryor
Positions
- Staff Specialist Radiation Oncology, Princess Alexandra Hospital
- Director of Training Radiation Oncology, Princess Alexandra Hospital
- Adjunct Associate Professor, APCRC-Q, Faculty of Health, Queensland University of Technology
- Radiation Oncologist, Greenslopes Private Hospital
- Senior Lecturer, School of Medicine, University of Queensland
Qualifications
FRANZCR, Fellow, Royal Australian and New Zealand College of Radiologists, Faculty of Radiation Oncology (), Australia, 2011
Bachelor of Medicine and Surgery (Honours), University of Queensland, Australia,2001
Bachelor of Science, University of Queensland, Australia, 1997
Biography
Dr David Pryor is a radiation oncologist specialising in the management of urological cancers and is the Director of Training in Radiation Oncology at the Princess Alexandra Hospital. He is the clinical lead for the stereotactic body radiotherapy (SBRT) program at the Princess Alexandra Hospital, implementing SBRT for prostate and kidney cancers and is chair of a national study evaluating the role of SBRT in patients with limited sites of metastatic spread of their prostate cancer (termed oligometastases). He is actively involved in developing collaborative, multicentre clinical trials evaluating SBRT in the management of prostate cancer and is the current chair of the Genitourinary Committee of the Trans-Tasman Radiation Oncology collaborative trials group (TROG).
Dr Pryor is an Adjunct Associate Professor with APCRC-Q and has an active clinical research program with special interests in precision radiotherapy (including SBRT), its combination with systemic agents and the incorporation of functional imaging to guide radiation treatment and response. His collaborations with APCRC-Q focus on quality improvement through clinical outcome registries and pre-clinical models of precision radiotherapy.
Dr Pryor is the clinical lead for the Prostate Cancer Outcomes Registry (PCOR) in Queensland and member of the PCOR-ANZ national steering committee. He is involved in developing and monitoring quality indicators to measure the quality of care provided to prostate cancer patients in Australia.
Dr Pryor is also lead clinical investigator on the Queensland node of the Prostate Cancer Outcomes – Compare & Reduce Variation study, which is a global project designed to improve quality of care and patient reported outcomes in men with localised prostate cancer.
Awards and grants
Awards
|
Year |
Title |
|
2010 |
RANZCR Hospira Withers and Peters Fellowship Prize |
|
2009 |
RANZCR Part II examination – Uhr Clarke Bursary |
|
2007 |
RANZCR Part I examination – CE Eddy Prize |
Grants
|
Year/Duration |
Funding Agency (in full at first use then abbreviate for subsequent use) |
Title |
Investigators (Initial Surname) |
|
2011-2013 |
National Health and Medical Research Council |
Squamous cell carcinomas of the head and neck: Exploring the role of human papillomavirus infection |
A Antonsson, R Neale, W Coman, S Porceddu, D Pryor, J Dillner |
Research interests
Prostate and urological cancers, gastrointestinal tumours, soft tissue tumours (sarcomas).
The use of functional imaging for disease characterisation and response assessment.
The use of highly focused, stereotactic body radiotherapy for primary and oligometastatic disease.
Current research projects
CO-CHAIR, TRIAL MANAGEMENT COMMITTEE
CORE – A multistage multi-centre international randomised trial of conventional care or radioablation (stereotactic body radiotherapy) for extra-cranial oligometastatic disease in lung,breast and prostate cancer.
TRIAL QUALITY ASSURANCE COMMITTEE
ANZUP 1303 (ENZARAD) - Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.
LOCAL PRINCIPLE INVESTIGATOR
ANZUP 1303 (ENZARAD) - Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.
ANZUP 1304 (ENZAMET) - Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer.
PROMETHEUS - A Phase 2 Multicentre Clinical Trial Exploring Stereotactic Radiotherapy Boost to the Prostate with Fractionated External Beam Radiotherapy
Top publications
Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, Nelson C, Martin J. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol 2014 - DOI 10.1007/s00432-014-1775-3
SV Porceddu, DI Pryor, E Burmeister et al. Results of a Prospective Study of PET-directed Management of Residual Nodal Abnormalities in Node Positive Head and Neck Cancer Following Definitive Radiotherapy with or without Systemic Therapy. Head Neck 2011; Dec;33(12):1675-82.
DI Pryor, SV Porceddu, BH Burmeister et al. Enhanced toxicity with cetuximab and radiotherapy in head and neck cancer. Radiotherapy and Oncology; 2009, 90, 172–176.
DI Pryor, B Solomon, SV Porceddu. The Emerging Era of Personalized Therapy in Squamous Cell Carcinoma of the Head and Neck. Asia Pacific Journal of Clinical Oncology; 2011 Sep;7(3):236-51.
Pryor, D. I., Porceddu, S. V., Scuffham, P. A., Whitty, J. A., Thomas, P. A. and Burmeister, B. H. (2013), Economic analysis of FDG-PET–guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. Head Neck, 35: 1287–1294. doi: 10.1002/hed.23108
Collaborators
- Colleen Nelson AM Executive Director, APCRC-Q
- Elizabeth Williams Head, Tumour Models, APCRC-Q
- Handoo Rhee Urology Research Fellow, Princess Alexandra Hospital
- Ian Vela Urologic Oncologist, Princess Alexandra Hospital, Department of Urology
- Margot Lehman Senior Staff Specialist, Radiation Oncology, Princess Alexandra Hospital
- Sonja Greenslade Radiologist, Princess Alexandra Hospital
- Brett Hollier Head, Invasion & Metastasis, APCRC-Q
